Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × canakinumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Rheumatoid Arthritis, Systemic Juvenile 1 Periodic Fevers Syndrome 1 Neoplasm Metastasis 1 Mevalonate Kinase Deficiency 1 Metastatic Pancreatic Ductal Adenocarcinoma 1 Melanoma 1 Cryopyrin-Associated Periodic Syndromes 1 Carcinoma 1 Bronchiolitis Obliterans Syndrome 1 Arthritis, Juvenile 1 Arthralgia 1

Interventions

Ipilimumab 79 pembrolizumab 71 Nivolumab 68 aldesleukin 46 Cyclophosphamide 44 Interleukin-2 33 fludarabine phosphate 30 Vemurafenib 29 Dacarbazine 28 trametinib 25 fludarabine 25 dabrafenib 25 Temozolomide 21 Bevacizumab 15 Radiosurgery 14 binimetinib 12 Paclitaxel 12 Introns 12 Interferon alpha-2 12 Carboplatin 11 CTLA-4 Antigen 11 peginterferon alfa-2b 9 montanide ISA 51 9 encorafenib 9 cobimetinib 9 Radiotherapy 9 talimogene laherparepvec 8 atezolizumab 8 Sorafenib 8 spartalizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03484923 2024-06-18

PLATforM

Novartis

Phase 2 Completed

196 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡